Melatonin receptor agonists in neurodegenerative diseases and psychiatric disorders
DOI:
https://doi.org/10.12775/QS.2024.22.54717Keywords
melatonin, agomelatine, ramelteon, tasimelteon, melatoninergic receptors agonistsAbstract
Neurodegenerative and psychiatric diseases remain a therapeutic challenge. Mental illnesses such as depression and bipolar affective disorder lead to disruption of the diurnal rhythm of melatonin secretion and disruption of the sleep-wake axis. The use of new melatonergic drugs has received special attention in recent years. Selective melatoninergic M1 and M2 receptor agonists (tasimelteon, ramelteon) show a more favorable metabolic profile, better regulation of circadian rhythms, and effects on total sleep time and sleep quality compared to the already well-studied melatonin. In addition, these drugs show no addictive potential. Agomelatine, through its action on M1 and M2 receptors, as well as serotonergic 5-HT2C and 5-HT2B receptors, exhibits antidepressant, normothymic, and neuroprotective effects, providing primary therapy or adjunctive treatment.
References
Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci. 2022;23(3):1851. Published 2022 Feb 6. doi:10.3390/ijms23031851
Won E, Na KS, Kim YK. Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression. Int J Mol Sci. 2021;23(1):305. Published 2021 Dec 28. doi:10.3390/ijms23010305
Monika Stanek's MSc thesis “The role of melatonin in mood disorders and the antidepressant effects of agomelatine”.
Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother. 2015;16(11):1669-1681. doi:10.1517/14656566.2015.1059424
Webler RD, Berg H, Fhong K, et al. The neurobiology of human fear generalization: meta-analysis and working neural model. Neurosci Biobehav Rev. 2021;128:421-436. doi:10.1016/j.neubiorev.2021.06.035
Millan MJ. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol. 2022;12:20451253221105128. Published 2022 Jun 30. doi:10.1177/20451253221105128
Rybakowski J. Etiopathogenesis of bipolar affective disorder - the state of the art for 2021. Etiopatogeneza choroby afektywnej dwubiegunowej – stan wiedzy na rok 2021. Psychiatr Pol. 2021;55(3):481-496. doi:10.12740/PP/132961
Bielecki JE, Gupta V. Cyclothymic Disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 17, 2023.
Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia. 2005;46 Suppl 4:8-13. doi:10.1111/j.1528-1167.2005.463003.x
Steen OD, Ori APS, Wardenaar KJ, van Loo HM. Loneliness associates strongly with anxiety and depression during the COVID pandemic, especially in men and younger adults. Sci Rep. 2022;12(1):9517. Published 2022 Jun 9. doi:10.1038/s41598-022-13049-9
De Berardis D, Orsolini L, Serroni N, Girinelli G, Iasevoli F, Tomasetti C, Mazza M, Valchera A, Fornaro M, Perna G, Piersanti M, Di Nicola M, Cavuto M, Martinotti G, Di Giannantonio M. The role of melatonin in mood disorders. ChronoPhysiology and Therapy. 2015;5:65-75 doi: 10.2147/CPT.S41761
Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol. 2014;6:127-137. Published 2014 Sep 18. doi:10.2147/CPAA.S36600
Elizabeth R. Super, Kyle P. Johnson,Chapter 36 - Sleep Pharmacotherapeutics for Pediatric Insomnia:: FDA-Approved and Off-Label Evidence,Editor(s): Teri J. Barkoukis, Jean K.Matheson, Richard Ferber, Karl Doghramji,Therapy in Sleep Medicine,W.B. Saunders,2012, Pages 457-464, ISBN 9781437717037, doi:10.1016/B978-1-4377-1703-7.10036-2.
Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15(1):32-51. doi:10.1111/j.1755-5949.2008.00066.x
Keating GM. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016;30(5):461-468. doi:10.1007/s40263-016-0330-y
Czernikiewicz A, Szulc AA, Sosnowska M, Zielińska-Wieniawska A, Feldman M, Murawiec S. POST APA 2014 - Warszawa 27 czerwca 2014 roku. Psychiatria. 2014;11:187–191.
Polymeropoulos CM, Polymeropoulos VM, Czeisler EL, et al. Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial. Front Neurol. 2022;13:901467. Published 2022 Sep 15. doi:10.3389/fneur.2022.901467
Tordjman S, Chokron S, Delorme R, et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr Neuropharmacol. 2017;15(3):434-443. doi:10.2174/1570159X14666161228122115
Al-Zaqri N, Pooventhiran T, Alsalme A, Warad I, John AM, Thomas R. Structural and physico-chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding with novel coronavirus proteins. J Mol Liq. 2020;318:114082. doi:10.1016/j.molliq.2020.114082
AXELROD J, WEISSBACH H. Enzymatic O-methylation of N-acetylserotonin to melatonin. Science. 1960;131(3409):1312. doi:10.1126/science.131.3409.1312
Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186-195. doi:10.1056/NEJM199701163360306
Savage RA, Zafar N, Yohannan S, Miller JMM. Melatonin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 9, 2024.
Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361-383. doi:10.1146/annurev-pharmtox-010814-124742
De Crescenzo F, Lennox A, Gibson JC, et al. Melatonin as a treatment for mood disorders: a systematic review. Acta Psychiatr Scand. 2017;136(6):549-558. doi:10.1111/acps.12755
Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012;21(10):1503-1522. doi:10.1517/13543784.2012.711314
Repova K, Baka T, Krajcirovicova K, et al. Melatonin as a Potential Approach to Anxiety Treatment. Int J Mol Sci. 2022;23(24):16187. Published 2022 Dec 19. doi:10.3390/ijms232416187
Davies SK, Ang JE, Revell VL, et al. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci U S A. 2014;111(29):10761-10766. doi:10.1073/pnas.1402663111
Madsen BK, Zetner D, Møller AM, Rosenberg J. Melatonin for preoperative and postoperative anxiety in adults. Cochrane Database Syst Rev. 2020;12(12):CD009861. Published 2020 Dec 8. doi:10.1002/14651858.CD009861.pub3
Manchia M, Squassina A, Pisanu C, et al. Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. Int J Bipolar Disord. 2019;7(1):27. Published 2019 Dec 9. doi:10.1186/s40345-019-0163-y
Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res. 1996;63(2-3):219-222. doi:10.1016/0165-1781(96)02910-1
Cervantes P, Gelber S, Kin FN, Nair VN, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci. 2001;26(5):411-416.
Kennedy SH, Tighe S, McVey G, Brown GM. Melatonin and cortisol "switches" during mania, depression, and euthymia in a drug-free bipolar patient. J Nerv Ment Dis. 1989;177(5):300-303. doi:10.1097/00005053-198905000-00009
Lam RW, Berkowitz AL, Berga SL, Clark CM, Kripke DF, Gillin JC. Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res. 1990;33(2):129-134. doi:10.1016/0165-1781(90)90066-e
Nathan PJ, Burrows GD, Norman TR. Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology. 1999;21(3):408-413. doi:10.1016/S0893-133X(99)00018-4
Bersani G, Garavini A. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(2):185-191. doi:10.1016/s0278-5846(99)00097-4
Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA, Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J Clin Psychiatry. 1997;58(9):383-388. doi:10.4088/jcp.v58n0902
Melrose S. Seasonal Affective Disorder: An Overview of Assessment and Treatment Approaches. Depress Res Treat. 2015;2015:178564. doi:10.1155/2015/178564
Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. World J Biol Psychiatry. 2006;7(3):138-151. doi:10.1080/15622970600571822
Leppämäki S, Partonen T, Vakkuri O, Lönnqvist J, Partinen M, Laudon M. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur Neuropsychopharmacol. 2003;13(3):137-145. doi:10.1016/s0924-977x(02)00175-x
Danilenko KV, Putilov AA. Melatonin treatment of winter depression following total sleep deprivation: waking EEG and mood correlates. Neuropsychopharmacology. 2005;30(7):1345-1352. doi:10.1038/sj.npp.1300698
Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171(15):3604-3619. doi:10.1111/bph.12720
Landowski J. Agomelatine - original antidepressant drug. Psychiatry. 2012; 9(1): 11–20.
Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378(9791):621-631. doi:10.1016/S0140-6736(11)60095-0
San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008;23(6):396-402. doi:10.1016/j.eurpsy.2008.04.002
Su Q, Li T, Liu GW, et al. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease. Neural Regen Res. 2023;18(4):727-733. doi:10.4103/1673-5374.353479
Siwek M, Wasik A, K rupa A. Agomelatine– pharmacological properties
and use in psychiatric practice. Psychiatr Psychol Klin. 2019; 19(2):
–203. doi:10.15557/PiPK.2019.0019
Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-964. doi:10.1124/jpet.103.051797
Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci. 2018;210:177-184. doi:10.1016/j.lfs.2018.09.003
Hill RA, Murray SS, Halley PG, Binder MD, Martin SJ, van den Buuse M. Brain-derived neurotrophic factor expression is increased in the hippocampus of 5-HT(2C) receptor knockout mice. Hippocampus. 2011;21(4):434-445. doi:10.1002/hipo.20759
Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem. 2006;43(Pt 5):344-353. doi:10.1258/000456306778520142
Gahr M. Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks. Curr Neuropharmacol. 2014;12(5):287-398. doi:10.2174/1570159X12999140619122914
Corruble E, de Bodinat C, Belaïdi C, Goodwin GM; agomelatine study group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16(10):2219-2234. doi:10.1017/S1461145713000679
Boulle F, Massart R, Stragier E, et al. Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Transl Psychiatry. 2014;4(11):e485. Published 2014 Nov 25. doi:10.1038/tp.2014.125
Kennedy SH, Eisfeld BS. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatr Dis Treat. 2007;3(4):423-428.
Almeida OP, Pfaff JJ. Sleep complaints among older general practice patients: association with depression. Br J Gen Pract. 2005;55(520):864-866.
Lewy AJ, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol Int. 2006;23(1-2):403-412. doi:10.1080/07420520500545862
Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23(7):571-585. doi:10.1002/hup.964
Weissmann D, van der Laan S, Underwood MD, et al. Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. Transl Psychiatry. 2016;6(8):e878. Published 2016 Aug 30. doi:10.1038/tp.2016.121
Kennedy SH, Avedisova A, Belaïdi C, Picarel-Blanchot F, de Bodinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016;26(2):378-389. doi:10.1016/j.euroneuro.2015.09.006
Kennedy SH, Avedisova A, Giménez-Montesinos N, Belaïdi C, de Bodinat C; Agomelatine Study Group. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder. Eur Neuropsychopharmacol. 2014;24(4):553-563. doi:10.1016/j.euroneuro.2014.01.006
Khoo AL, Zhou HJ, Teng M, et al. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs. 2015;29(8):695-712. doi:10.1007/s40263-015-0267-6
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. doi:10.1016/S0140-6736(17)32802-7
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;2013(12):CD008851. Published 2013 Dec 17. doi:10.1002/14651858.CD008851.pub2
Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG. The preclinical discovery and development of agomelatine for the treatment of depression. Expert Opin Drug Discov. 2020;15(10):1121-1132. doi:10.1080/17460441.2020.1781087
Miklowitz DJ, Johnson SL. The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol. 2006;2:199-235. doi:10.1146/annurev.clinpsy.2.022305.095332
Magioncalda P, Martino M. A unified model of the pathophysiology of bipolar disorder. Mol Psychiatry. 2022;27(1):202-211. doi:10.1038/s41380-021-01091-4
Calabrese JR, Guelfi JD, Perdrizet-Chevallier C; Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9(6):628-635. doi:10.1111/j.1399-5618.2007.00507.x
Mahableshwarkar AR, Calabrese JR, Macek TA, et al. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. J Affect Disord. 2017;221:275-282. doi:10.1016/j.jad.2017.06.044
Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry. 2016;208(1):78-86. doi:10.1192/bjp.bp.114.147587
Kaminski-Hartenthaler A, Nussbaumer B, Forneris CA, et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2015;(11):CD011271. Published 2015 Nov 11. doi:10.1002/14651858.CD011271.pub2
Nussbaumer-Streit B, Greenblatt A, Kaminski-Hartenthaler A, et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2019;6(6):CD011271. Published 2019 Jun 17. doi:10.1002/14651858.CD011271.pub3
Tchekalarova J, Stoynova T, Ilieva K, Mitreva R, Atanasova M. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light. Pharmacol Biochem Behav. 2018;171:1-9. doi:10.1016/j.pbb.2018.05.016
Santos P, Herrmann AP, Elisabetsky E, Piato A. Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review. Braz J Psychiatry. 2019;41(2):168-178. doi:10.1590/1516-4446-2018-0005
Stein DJ, Ahokas A, Jarema M, et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2017;27(5):526-537. doi:10.1016/j.euroneuro.2017.02.007
Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561-566. doi:10.1097/JCP.0b013e318184ff5b
Stein DJ, Khoo JP, Ahokas A, et al. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharmacol. 2018;28(8):970-979. doi:10.1016/j.euroneuro.2018.05.006
Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002-1008. doi:10.4088/JCP.11m07493
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nicola Dyrek, Magdalena Balwierz, Marcin Łata, Agnieszka Kosińska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 104
Number of citations: 0
